Sushma Koneru, MD
Advanced Heart Failure and Transplant Cardiology · Orlando, FLNPI 1457572547
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 146 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in FL, where the typical reported total is $7,029.
Across 146 payments — averaging $47.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kestra Medical Technology Services, Inc.$1K
- Abbott$622
- E.r. Squibb & Sons, L.L.C.$468
- AstraZeneca$426
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$352
- Abiomed$323
- plus $4K from 29 others
Across 20 payments — averaging $941.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim Pharma GmbH & Co.kg$11K
- Boehringer Ingelheim International GmbH$8K
What the payments were for
- Food & beverage$6,874100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kestra Medical Technology Services, Inc. | 13 | $1,135 |
| Abbott | 6 | $622 |
| E.r. Squibb & Sons, L.L.C. | 13 | $468 |
| AstraZeneca | 12 | $426 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $352 |
| Abiomed | 5 | $323 |
| Shockwave Medical, Inc | 2 | $314 |
| Cvrx, Inc. | 6 | $304 |
| Amgen | 5 | $302 |
| United Therapeutics Corporation | 4 | $284 |
| Medtronic | 3 | $221 |
| Boston Scientific | 3 | $198 |
| Pfizer | 9 | $192 |
| Merck | 9 | $191 |
| Alnylam Pharmaceuticals Inc. | 5 | $175 |
| Impulse Dynamics (USA) Inc. | 1 | $171 |
| Esperion Therapeutics, Inc. | 4 | $159 |
| Heartflow, Inc. | 5 | $159 |
| Boehringer Ingelheim | 3 | $152 |
| Johnson & Johnson | 2 | $148 |
| Atricure, Inc. | 3 | $117 |
| Bridgebio Pharma, Inc. | 4 | $100 |
| Sanofi-aventis U.S. LLC | 2 | $55 |
| Biosense Webster, Inc. | 2 | $54 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $40 |
| Actelion Pharmaceuticals US, Inc. | 1 | $31 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $23 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Kowa Pharmaceuticals America, Inc. | 1 | $21 |
| Bayer | 1 | $21 |
| Novartis | 1 | $21 |
| Philips North America LLC | 1 | $19 |
| Livanova USA, Inc. | 1 | $16 |
| Scpharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Assure WCD$845
- OPTIMIZER$342
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$314
- Repatha$251
- ORENITRAM$247
- AMPLATZER Occluders$184
- WATCHMAN Access System$162
- Barostim Neo System$146
- CARDIOMEMS$145
- VenaSeal$140
- XARELTO$129
- WAINUA$129
- MitraClip$125
- MitraClip System$120
- CAMZYOS$108
- NEXLETOL$105
- JARDIANCE$104
How this compares
$6,874 in reported general payments places this provider in the 45th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.
See all advanced heart failure and transplant cardiology providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 59 | $1,714,941 |
| AmvuttraVutrisiran Sodium | 12 | $1,363,347 |
| FarxigaDapagliflozin Propanediol | 162 | $208,776 |
| EntrestoSacubitril/Valsartan | 106 | $167,947 |
| EliquisApixaban | 120 | $144,727 |
| JardianceEmpagliflozin | 64 | $77,938 |
| Repatha SureclickEvolocumab | 19 | $26,220 |
| VerquvoVericiguat | 14 | $24,504 |
| XareltoRivaroxaban | 16 | $20,716 |
| BrilintaTicagrelor | 11 | $7,550 |
| Isosorbide Dinitrate | 23 | $2,087 |
| Torsemide | 62 | $1,757 |
| Midodrine Hcl | 19 | $1,673 |
| Ezetimibe | 40 | $1,624 |
| Metoprolol Succinate | 100 | $1,322 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $192 | $1,859,668179 claims |
| Alnylam Pharmaceuticals Inc.Amvuttra | $175 | $1,363,34712 claims |
| AstraZenecaFarxiga, Brilinta | $426 | $216,326173 claims |
| NovartisEntresto | $21 | $167,947106 claims |
| Boehringer IngelheimJardiance | $152 | $77,93864 claims |
| MerckVerquvo | $191 | $24,50414 claims |
| Johnson & JohnsonXarelto | $148 | $20,71616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.
Other advanced heart failure and transplant cardiology in Orlando
- Naveen BellamOrlando$414K
- Stacy MandrasOrlando$100K
- Pujan PatelOrlando$66K
- Andrija VidicOrlando$18K
- Shahid QamarOrlando$9K
- Jacqueline DoweOrlando$7K
- Mauricio VelezOrlando$6K
- Akanksha AgrawalOrlando$5K
- Krithika KrishnaraoOrlando$4K
- Maria DemoriOrlando$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.